- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04752618
Safe Mothers, Safe Children Initiative (SMSC)
November 15, 2023 updated by: New York University
Treating Maternal PTSD to Enhance and Reduce Maltreatment Recidivism: Safe Mothers, Safe Children
The purpose of this study is to assess the efficacy of the combined interventions, Skills Training in Affective and Interpersonal Regulation (STAIR) and Parent-Child Interaction Therapy (PCIT) or P-STAIR, for treating maternal PTSD and reducing maltreatment recidivism.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This study is a two-arm randomized controlled trial (RCT): P-STAIR (23 sessions) vs. supportive counseling (SC) (23 sessions).
Eligible cases are randomized to P-STAIR and SC in a 1:1 ratio.
Participants will be mothers receiving family preservation services (FPS), with a child in the age range of 1-8 years old, and PTSD (with/without depression).
Symptom progress will be measured at pre-treatment, two in-treatment assessments (9 weeks and 16 weeks), post-treatment, and at a 6-month follow-up.
Study Type
Interventional
Enrollment (Estimated)
160
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kathleen Brody
- Phone Number: 84296 212-998-4296
- Email: kathleen.brody@nyu.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10003
- Recruiting
- McSilver Institute for Poverty Policy and Research
-
Contact:
- Michael A Lindsey
- Phone Number: 212-998-5927
- Email: ml4361@nyu.edu
-
Contact:
- Ammu Kowolik
- Email: ammu@nyu.edu
-
Principal Investigator:
- Michael A Lindsey
-
Sub-Investigator:
- Kathrine Sullivan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Receiving preventive services
- Meeting a severity score of 28 or higher OR probable DSM-5 diagnostic criteria for PTSD (PDS-5)
- Having 1-8-year-old child
- Being the legal guardian for the child with physical and legal custody
- Being able to read, write, and speak English or Spanish
Exclusion Criteria:
- Having suicidal ideation present in the past month prior to pre-assessment or reports of a suicide attempt in the past year (SCID-5)
- Meeting a diagnosis of severe substance or alcohol use disorder (≥ 6 symptoms on SCID) AND not in early remission (≥3 months without meeting any substance or alcohol use disorder criteria (except craving)
- Having current or active symptoms of psychosis in the past month
- Having a disability affecting communication, such as deafness
- Having an index child with a developmental condition that impedes cognitive and/or physical functioning, e.g. autism
- Having an index child with current symptoms or diagnosis of psychosis as defined by the DSM-5 in the past 3 months
- Experiencing current or history of intimate partner violence (IPV) or family violence:
If there is a history of IPV/family violence and the relationship is no longer active, the relationship must have ended for at least ninety days with no intention of restarting; If there is a history of IPV/family violence, but the relationship is ongoing, there must not have been an IPV/family violence event for at least one year
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: P-STAIR
Participants will receive 23 weekly individual treatment sessions.
Each session will last one hour.
P-STAIR is a combination of STAIR and PCIT.
STAIR focuses on reduction of PTSD symptoms through enhancement of emotion regulation skills.
PCIT focuses on the reduction of negative parenting skills and the increase of positive parenting skills.
|
PCIT+ STAIR
|
Active Comparator: Supportive Counseling
Participants will receive 23 weekly individual treatment sessions.
Each session will last one hour.
Supportive counseling has been modified to permit non-trauma discussion of parenting problems.
Each session is client-directed and clinicians take an unconditionally supportive role.
|
Non-trauma focused psychotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Post-traumatic Stress Diagnostic Scale for the DSM-5 (PDS-5)
Time Frame: Change from baseline (pre-treatment) to mid-treatment at session 9 and 16 to upon completion of treatment (an average of 43 weeks) to six-month follow-up after treatment completion
|
Post-traumatic Stress Diagnostic Scale for the DSM-5 (PDS-5) is a 24-item self-report measure of PTSD symptoms over the last month.
Items are rated on a 5-point scale of frequency and severity ranging from 0 ("not at all") to 4 ("6 or more times a week/severe").
Higher scores indicate more severe PTSD symptoms.
PDS-5 will be used to monitor change in PTSD symptoms over treatment implementation.
PDS-5 is also used during the baseline to evaluate for inclusion/exclusion criteria.
|
Change from baseline (pre-treatment) to mid-treatment at session 9 and 16 to upon completion of treatment (an average of 43 weeks) to six-month follow-up after treatment completion
|
Center for Epidemiological Studies-Depression (CES-D)
Time Frame: Change from baseline (pre-treatment) to mid-treatment at session 9 and 16 to upon completion of treatment (an average of 43 weeks) to six-month follow-up after treatment completion
|
Center for Epidemiological Studies-Depression (CES-D) is a 20-item self-report measure of symptoms associated with depression, such as restless sleep, poor appetite, and feeling lonely.
Items are rated on a 3-point scale ranging from 0 ("rarely or none of the time") to 3 ("most or almost all of the time").
Scores range from 0 to 60, with high scores indicating greater depressive symptoms.
CES-D will be used to assess change in depression symptoms over treatment implementation.
|
Change from baseline (pre-treatment) to mid-treatment at session 9 and 16 to upon completion of treatment (an average of 43 weeks) to six-month follow-up after treatment completion
|
Dyadic Parent-Child Interaction Coding System-IV (DPICS)
Time Frame: Change from baseline (pre-treatment) to mid-treatment at session 16 to upon completion of treatment (an average of 43 weeks) to six-month follow-up after treatment completion
|
Dyadic Parent-Child Interaction Coding System-IV (DPICS) examines the quality of parent-child social interaction in three 5-minute situations: child-directed play, parent-directed play, and clean-up.
Positive skills include praise, reflect, and describe, and negative skills include questions, commands, and criticisms.
Observations are coded by trained DPICS scorers to produce total scores.
DPICS scores allow us to track the changes in positive and negative parenting scores over treatment implementation.
|
Change from baseline (pre-treatment) to mid-treatment at session 16 to upon completion of treatment (an average of 43 weeks) to six-month follow-up after treatment completion
|
New foster care removals
Time Frame: Every six-months for 10 years
|
Data is collected through the New York State Child Welfare Registry (NYSCWR) semi-annually on the number of out-of-home placements for 10 years for completers and non-completers who have consented into the study.
Number of new foster care removals are located by unique NYSCWR identifiers collected at time of consent.
Out-of-home placement data, in addition to new substantiated welfare reports, will be used to assess recidivism.
|
Every six-months for 10 years
|
New child abuse/neglect welfare reports
Time Frame: Every six-months for 10 years
|
Data is collected through the New York State Child Welfare Registry (NYSCWR) semi-annually on the number of substantiated abuse/neglect reports for 10 years for completers and non-completers who have consented into the study.
Number of new substantiated reports are located by unique NYSCWR identifiers collected at time of consent.
New substantiated welfare reports, as well as out-of-home placement data, will be used to assess recidivism.
|
Every six-months for 10 years
|
Family Preservation Services Usual Care (FPSUC) reports
Time Frame: Throughout study completion, an average 43 weeks
|
Family Preservation Services Usual Care (FPSUC) is extracted from electronic records that agencies use to document services.
FPSUC details the number of services accessed in preventative agencies for clients.
Data will be used to statistically control for FPSUC.
|
Throughout study completion, an average 43 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Structured Clinical Interview for DSM-5 (SCID-5)
Time Frame: Change from baseline (pre-treatment) to mid-treatment at session 16 to upon completion of treatment (an average of 43 weeks) to six-month follow-up after treatment completion
|
Structured Clinical Interview for DSM-5 (SCID-5) is the gold standard for determining DSM-5 Axis I current diagnoses and psychiatric history.
The SCID-5 depression, alcohol and substance use, and psychosis modules will be used.
SCID-5 will be used to track changes in depression, substance use/abuse, and symptoms of psychosis, as well as to evaluate inclusion/exclusion criteria.
|
Change from baseline (pre-treatment) to mid-treatment at session 16 to upon completion of treatment (an average of 43 weeks) to six-month follow-up after treatment completion
|
Difficulties in Emotion Regulation Scale (DERS)
Time Frame: Change from baseline (pre-treatment) to mid-treatment at session 9 and 16 to upon completion of treatment (an average of 43 weeks) to six-month follow-up after treatment completion
|
Difficulties in Emotion Regulation Scale (DERS) is a 36-item self-report measure used to assesses emotion regulation.
Items are rated on a scale of 1 ("almost never [0-10%]") to 5 ("almost always [91-100%]").
Higher scores indicate more difficulty in emotion regulation.
DERS has adequate construct and predictive validity and good test-retest reliability.
DERS will be used to evaluate level of emotion regulation skills during treatment implementation.
|
Change from baseline (pre-treatment) to mid-treatment at session 9 and 16 to upon completion of treatment (an average of 43 weeks) to six-month follow-up after treatment completion
|
Adult Adolescent Parenting Inventory-2.1 (AAPI-2.1)
Time Frame: Change from baseline (pre-treatment) to end of treatment (average 43 weeks) to six-month follow-up
|
Adult Adolescent Parenting Inventory-2.1 (AAPI-2.1) is a self-reporting inventory that measures parental behaviors and is commonly used to assess the risk of child abuse and neglect.
Items are rated on a scale of 1 ("strongly agree") to 5 ("strongly disagree").
AAPI-2.1 has five sub-constructs: expectations of children, parental empathy towards children's needs, use of corporal punishment, parent-child family roles, and children's power and independence.
Higher scores indicate lower risk of parental abuse/neglect.
AAPI will be used to monitor the change in parental behaviors over treatment implementation.
|
Change from baseline (pre-treatment) to end of treatment (average 43 weeks) to six-month follow-up
|
Treatment Services Review (TSR)
Time Frame: Baseline (pre-treatment)
|
Treatment Services Review (TSR) is an interview used to gather information about specific mental health services received outside of the study treatment, lifetime treatment history, and treatment received at the time of the baseline (pre) assessment.
It describes treatment type (individual therapy vs. group), provider type (psychologist, psychiatrist, social worker), length (in years) and frequency of treatment (rate of appointments), rate of hospitalizations, and medications prescribed.
|
Baseline (pre-treatment)
|
Treatment Services Review (TSR)
Time Frame: End of treatment (an average 43 weeks)
|
Treatment Services Review (TSR) is an interview used to gather information about specific mental health services received outside of the study treatment, lifetime treatment history, and treatment received during treatment implementation.
It describes treatment type (individual therapy vs. group), provider type (psychologist, psychiatrist, social worker), length (in years) and frequency of treatment (rate of appointments), rate of hospitalizations, and medications prescribed.
|
End of treatment (an average 43 weeks)
|
Treatment Services Review (TSR)
Time Frame: Follow-up after treatment completion (six-months after end of treatment)
|
Treatment Services Review (TSR) is an interview used to gather information about specific mental health services received outside of the study treatment, lifetime treatment history, and treatment received between the end of treatment and the six-month follow-up assessment.
It describes treatment type (individual therapy vs. group), provider type (psychologist, psychiatrist, social worker), length (in years) and frequency of treatment (rate of appointments), rate of hospitalizations, and medications prescribed.
|
Follow-up after treatment completion (six-months after end of treatment)
|
Therapy Acceptability and Expectations (TAE)
Time Frame: Change from baseline (pre-treatment) to mid-treatment at session 9 and 16 to upon completion of treatment (an average of 43 weeks) to six-month follow-up after treatment completion
|
Therapy Acceptability and Expectations (TAE) is a 5-item scale that evaluates credibility and engagement of study treatment.
Items range from 0 ("not at all") to 8 ("extremely").
Higher scores indicate greater acceptability of treatment.
TAE is administered throughout treatment in order to assess the clinician-client therapeutic relationship and client engagement with treatment.
Necessary changes that arise from the TAE are addressed in future treatment sessions.
|
Change from baseline (pre-treatment) to mid-treatment at session 9 and 16 to upon completion of treatment (an average of 43 weeks) to six-month follow-up after treatment completion
|
Traumatic Events Screening Inventory - Parent Report Revised (TESI-PRR)
Time Frame: Baseline (pre-treatment)
|
Traumatic Events Screening Inventory - Parent Report Revised (TESI-PRR) is a 24-item parent-report measure for preschool-age children used to assess frequency and type of child exposure to traumatic events.
TESI-PRR is used to monitor exposure to traumatic events at the time of the baseline (pre) assessment.
|
Baseline (pre-treatment)
|
Traumatic Events Screening Inventory - Parent Report Revised (TESI-PRR)
Time Frame: End of treatment (an average 43 weeks)
|
Traumatic Events Screening Inventory - Parent Report Revised (TESI-PRR) is a 24-item parent-report measure for preschool-age children used to assess frequency and type of child exposure to traumatic events.
TESI-PRR is used to monitor exposure to traumatic events during treatment implementation.
|
End of treatment (an average 43 weeks)
|
Traumatic Events Screening Inventory - Parent Report Revised (TESI-PRR)
Time Frame: Follow-up after treatment completion (six-months after end of treatment)
|
Traumatic Events Screening Inventory - Parent Report Revised (TESI-PRR) is a 24-item parent-report measure for preschool-age children used to assess frequency and type of child exposure to traumatic events.
TESI-PRR is used to monitor exposure to traumatic events between the end of treatment and the six-month follow-up assessment.
|
Follow-up after treatment completion (six-months after end of treatment)
|
Strengths and Difficulties Questionnaire (SDQ)
Time Frame: Change from baseline (pre-treatment) to mid-treatment at session 9 and 16 to upon completion of treatment (an average of 43 weeks) to six-month follow-up after treatment completion
|
Strengths and Difficulties Questionnaire (SDQ) is a 25-item parent-report behavioral screening questionnaire that comprises five sub-scales: emotional symptoms, conduct problems, hyperactivity/inattention, peer relationship problems, and prosocial behavior.
Items have the following responses: "not true," "somewhat true," and "certainly true."
Higher scores indicate a higher likelihood of emotional and/or behavioral difficulties.
SDQ will be used throughout treatment to assess change in behavior of the child participating in the parent-child dyadic play observations.
|
Change from baseline (pre-treatment) to mid-treatment at session 9 and 16 to upon completion of treatment (an average of 43 weeks) to six-month follow-up after treatment completion
|
Children's Behavior Questionnaire - Very Short Form (CBQ-VSF)
Time Frame: Change from baseline (pre-treatment) to end of treatment (average 43 weeks) to six-month follow-up
|
Children's Behavior Questionnaire - Very Short Form (CBQ-VSF) is a 36-item parent-report of child temperament.
Responses are given on a 7-point scale ranging from 1 ("extremely untrue of my child") to 7 ("extremely true of my child").
The questionnaire has 3 sub-scales: surgency/extraversion, negative affectivity, and effortful control.
CBQ-VSF will be used throughout treatment to assess change in temperament of the child participating in the parent-child dyadic play observations.
|
Change from baseline (pre-treatment) to end of treatment (average 43 weeks) to six-month follow-up
|
Eyberg Child Behavior Inventory (ECBI)
Time Frame: Change from baseline (pre-treatment) to mid-treatment at session 9 and 16 to upon completion of treatment (an average of 43 weeks) to six-month follow-up after treatment completion
|
Eyberg Child Behavior Inventory (ECBI) is a 36-item parent-report designed to assess conduct issues in children ages 2-16.
ECBI asks parents to identify problems through "yes/no" questions.
The inventory examines the intensity of problems on a scale from 1 ("never") to 7 ("always").
Higher total problem scores indicate more behaviors are a problem for the parent.
Higher total intensity scores indicate higher frequency of behaviors.
ECBI will be used throughout treatment to assess change in behavior of the child participating in the parent-child dyadic play observations and rate of parental-identified problems.
|
Change from baseline (pre-treatment) to mid-treatment at session 9 and 16 to upon completion of treatment (an average of 43 weeks) to six-month follow-up after treatment completion
|
Clinician-administered Post-Traumatic Stress Disorder Scale for DSM-5 (CAPS-5)
Time Frame: Change from baseline (pre-treatment) to mid-treatment at session 16 to upon completion of treatment (an average of 43 weeks) to six-month follow-up after treatment completion
|
Clinician-administered Post-Traumatic Stress Disorder Scale for DSM-5 (CAPS-5) is a 30-item structured interview developed by the U.S. Department of Veterans Affairs National Center for PTSD.
It yields a categorical measure of diagnosis and a severity score.
Severity scores are calculated from 20 DSM-5 PTSD symptoms and range from 0 ("absent") to 80 ("extreme").
It has strong reliability/validity. CAPS-5, optional after baseline (pre-treatment), will be used to assess change in PTSD diagnosis criteria and severity over treatment implementation.
|
Change from baseline (pre-treatment) to mid-treatment at session 16 to upon completion of treatment (an average of 43 weeks) to six-month follow-up after treatment completion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Michael A Lindsey, New York University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2021
Primary Completion (Estimated)
September 30, 2025
Study Completion (Estimated)
September 30, 2025
Study Registration Dates
First Submitted
January 29, 2021
First Submitted That Met QC Criteria
February 9, 2021
First Posted (Actual)
February 12, 2021
Study Record Updates
Last Update Posted (Estimated)
November 17, 2023
Last Update Submitted That Met QC Criteria
November 15, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-FY2021-5220
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on P-STAIR
-
San Diego State UniversityCompletedPostprandial Blood GlucoseUnited States
-
Teesside UniversityCompletedBlood Pressure | Heart Rate | Physical Activity Enjoyment | High-intensity Interval Exercise | Rating of Perceived Exertion | Acute MoodUnited Kingdom
-
Harran UniversityCompleted
-
Cancer Institute and Hospital, Chinese Academy...Completed
-
Stanford UniversityEnrolling by invitationBorderline Personality Disorder | Posttraumatic Stress Disorder | Emotion RegulationUnited States
-
University of GeorgiaCompleted
-
San Diego State UniversityCompletedPostprandial Hyperglycemia
-
NYU Langone HealthWithdrawn
-
Kaohsiung Veterans General Hospital.CompletedChronic Stroke Patients
-
San Diego State UniversityRecruiting